For cardiologists and lipidologists attending the American Heart Association Scientific Sessions, full results from the Lp(a) HORIZON trial made disappointing listening as presentations confirmed the lack of effect of pelacarsen on cardiovascular outcomes, despite reductions in Lp(a) levels. However, many other research reports at the congress continued to spotlight Lp(a) as an important target for reducing CV risk in patients with elevated levels, together with the need for Lp(a) testing according to current guidelines and gaps in management of patients with raised Lp(a) in clinical practice today.
- Pelacarsen reduces Lp(a) levels but not CV outcomes
- Care gaps identified for patients with elevated Lp(a)
- Carotid ultrasound refines ASCVD risk stratification in patients with elevated Lp(a)
- Lp(a) but not non-Lp(a) apoB is prognostic for MACE
- Elevated Lp(a) and HFpEF risk
Reports by Jenny Bryan
